|
Market Closed -
Nasdaq
04:00:00 03/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 219.88 USD | -1.32% |
|
-3.39% | +24.94% |
| 10-03 | Biogen's experimental lupus drug shows benefit against skin symptoms | RE |
| 10-03 | Biogen Says Litifilimab Shows Efficacy in New 52-Week Phase 2 Data | MT |
| Market Cap | 32.49B 28.87B 26.94B 24.56B 46.31B 3,123B 46.74B 326B 126B 1,597B 122B 119B 5,124B | P/E 2026 * |
35.9x | P/E 2027 * | 19.4x |
|---|---|---|---|---|---|
| Enterprise Value | 37.42B 33.25B 31.04B 28.29B 53.35B 3,598B 53.85B 376B 146B 1,839B 141B 137B 5,903B | EV / Sales 2026 * |
3.58x | EV / Sales 2027 * | 3.28x |
| Free-Float |
85.8% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| BIIB | Delayed | |
CBOE
| BIIB | Real-time | |
|
Tradegate
| IDP | Real-time | |
|
Mexican S.E.
| BIIB * | End-of-day quote | |
|
Borsa Italiana
| 1BIIB | End-of-day quote | |
|
Deutsche Boerse AG
| IDP | Delayed | |
|
Xetra
| IDP | Delayed | |
|
Boerse Muenchen
| IDP | Real-time | |
|
Kazakhstan S.E.
| BIIB_KZ | End-of-day quote | |
|
Swiss Exchange
| BIIB | Delayed | |
|
Wiener Boerse
| BIIB | End-of-day quote | |
|
Börse Stuttgart
| IDP | Delayed | |
|
Santiago S.E.
| BIIB | End-of-day quote | |
|
Santiago S.E.
| BIIBCL | End-of-day quote | |
|
Swiss Exchange
| BIIB | Delayed |
Last Transcript: Biogen Inc.
| 1 day | -1.32% | ||
| 1 week | -3.39% | ||
| Current month | -2.66% | ||
| 1 month | -2.06% | ||
| 3 months | +1.74% | ||
| 6 months | +23.99% | ||
| Current year | +24.94% |
| 1 week | 219.81 |  | 230.49 |
| 1 month | 208.93 | | 230.49 |
| Current year | 160.36 | | 230.49 |
| 1 year | 138 | | 230.49 |
| 3 years | 110.04 | | 269.43 |
| 5 years | 110.04 | | 319.76 |
| 10 years | 110.04 | | 468.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 14/11/2022 | |
Robin Kramer
DFI | Director of Finance/CFO | 60 | 01/03/2025 |
Daniel Quirk
CTO | Chief Tech/Sci/R&D Officer | - | 28/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Eric Rowinsky
BRD | Director/Board Member | 69 | 23/03/2010 |
Stephen Sherwin
BRD | Director/Board Member | 77 | 01/01/2010 |
William Hawkins
BRD | Director/Board Member | 72 | 19/06/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/9/26 | Free | General Counsel | 7,405 | 0.0050% | ||
| 4/8/26 | Sell | Director | -593 | 0.0004% | ||
| 9/6/26 | Free | Director | 1,505 | 0.0010% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.32% | -3.39% | +37.53% | -12.51% | 32.49B | |
| -0.61% | -3.43% | +36.07% | +117.61% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.82% | 617B | |
| +1.11% | -0.58% | +12.36% | +78.27% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.79% | 356B | |
| -0.95% | -4.05% | +20.54% | +40.33% | 333B | |
| -1.46% | -2.89% | +10.57% | +26.54% | 267B | |
| -1.35% | -5.43% | -6.17% | +8.82% | 244B | |
| -1.04% | -2.79% | +35.30% | +54.42% | 218B | |
| -1.87% | -4.10% | +28.44% | +97.54% | 179B | |
| Average | -0.82% | -3.39% | +27.22% | +51.76% | 372.97B | |
| Weighted average by Cap. | -0.60% | -3.33% | +29.15% | +70.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.44B 9.28B 8.66B 7.89B 14.89B 1,004B 15.03B 105B 40.61B 513B 39.21B 38.36B 1,647B | 10.66B 9.47B 8.84B 8.06B 15.19B 1,025B 15.33B 107B 41.45B 524B 40.01B 39.15B 1,681B |
| Net income | 997M 886M 827M 753M 1.42B 95.82B 1.43B 10B 3.88B 48.99B 3.74B 3.66B 157B | 1.86B 1.65B 1.54B 1.4B 2.65B 179B 2.67B 18.65B 7.23B 91.35B 6.98B 6.83B 293B |
| Net Debt | 4.94B 4.39B 4.09B 3.73B 7.04B 475B 7.1B 49.54B 19.2B 243B 18.53B 18.13B 779B | 2.42B 2.15B 2.01B 1.83B 3.45B 233B 3.48B 24.29B 9.41B 119B 9.09B 8.89B 382B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | US$219.88 | -1.32% | 780,427 |
| 01/10/26 | US$222.82 | -1.35% | 1,755,492 |
| 30/09/26 | US$225.88 | -0.52% | 1,553,331 |
| 29/09/26 | US$227.07 | -0.71% | 1,161,173 |
| 28/09/26 | US$228.69 | +0.48% | 1,332,340 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIIB Stock
Select your edition
All financial news and data tailored to specific country editions
